Category Archives: C. diff. infection

Researchers Combined Efforts Will Hopefully Lead To Improved Recognition Of Clostridioides difficile Pathogen To Reduce the Suffering and Economic Losses Caused by a CDI

Clostridioides difficile Infection: The Challenge, Tests, and Guidelines



Clostridioides difficile is a dangerous human pathogen because it can grow to high numbers in the intestine, cause colitis with its potent toxins, and persist as spores. C. difficile infection (CDI) is the primary hospital-acquired infection in North America and Europe, and it now is a global disease. Even with newer laboratory tests, there still is confusion on accurately diagnosing this disease. Three guidelines from three different healthcare-affiliated societies have recently been published. Consensus consolidated recommendations from these guidelines should be recognized by healthcare professionals, who need to understand why this disease continues to be difficult to diagnose and need a clear understanding of the advantages and limitations of current tests. Hopefully, these combined efforts will lead to an improvement in the recognition of this pathogen and a reduction in the suffering and economic loss caused by CDI.




To review the publication in its entirety please click on the link below to be redirected:

Accessible Database for Clostridioides difficile Genome Sequences Supporting Transmission and Epidemics

  • Martinique Frentrup1​, Zhemin Zhou2​, Matthias Steglich1​,3​, Jan P. Meier-Kolthoff1​, Markus Göker1​, Thomas Riedel1​,3​, Boyke Bunk1​, Cathrin Spröer1​, Jörg Overmann1​,3​,4​, Marion Blaschitz5​, Alexander Indra5​, Lutz von Müller6​, Thomas A. Kohl7​,8​, Stefan Niemann7​,8​, Christian Seyboldt9​, Frank Klawonn10​,11​, Nitin Kumar12​, Trevor D. Lawley12​, Sergio García-Fernández13​,14​, Rafael Cantón13​,14​, Rosa del Campo13​,14​, Ortrud Zimmermann15​, Uwe Groß15​, Mark Achtman2​, Ulrich Nübel1​,3​,4​


Clostridioides difficile is the primary infectious cause of antibiotic-associated diarrhea. Local transmissions and international outbreaks of this pathogen have been previously elucidated by bacterial whole-genome sequencing, but comparative genomic analyses at the global scale were hampered by the lack of specific bioinformatic tools. Here we introduce a publicly accessible database within EnteroBase ( that automatically retrieves and assembles 

C. difficile short-reads from the public domain, and calls alleles for core-genome multilocus sequence typing (cgMLST). We demonstrate that comparable levels of resolution and precision are attained by EnteroBase cgMLST and single-nucleotide polymorphism analysis. EnteroBase currently contains 18 254 quality-controlled 

C. difficile genomes, which have been assigned to hierarchical sets of single-linkage clusters by cgMLST distances. This hierarchical clustering is used to identify and name populations of C. difficile at all epidemiological levels, from recent transmission chains through to epidemic and endemic strains. Moreover, it puts newly collected isolates into phylogenetic and epidemiological context by identifying related strains among all previously published genome data. For example, HC2 clusters (i.e. chains of genomes with pairwise distances of up to two cgMLST alleles) were statistically associated with specific hospitals (P<10−4) or single wards (P=0.01) within hospitals, indicating they represented local transmission clusters. We also detected several HC2 clusters spanning more than one hospital that by retrospective epidemiological analysis were confirmed to be associated with inter-hospital patient transfers. In contrast, clustering at level HC150 correlated with k-mer-based classification and was largely compatible with PCR ribotyping, thus enabling comparisons to earlier surveillance data. EnteroBase enables contextual interpretation of a growing collection of assembled, quality-controlled C. difficile genome sequences and their associated metadata. Hierarchical clustering rapidly identifies database entries that are related at multiple levels of genetic distance, facilitating communication among researchers, clinicians, and public-health officials who are combatting disease caused by C. difficile.


  • Clostridioides (Clostridium) difficile
  • nosocomial infection, 
  • genomic population structure, 
  • outbreak, 
  • cgMLST, 
  • hierarchical clustering

Author NotesAll supporting data, code and protocols have been provided within the article or through supplementary data files. Three supplementary tables and eight supplementary figures are available with the online version of this article.Sequence accession numbers: PRJEB33768, PRJEB33779, PRJEB33780.†These authors contributed equally to this work‡These authors also contributed equally to this work


CC, cgST complex; CDI, Clostridioides difficile infection; cgMLST, core-genome MLST; cgST, core-genome sequence type; HC150, hierarchical cluster with pairwise distances of up to 150 cgMLST alleles; HC, hierarchial cluster; HierCC, hierarchical clustering; MLST, multilocus sequence typing; ORF, open reading frame; rMLST, ribosomal MLST; rST, ribosomal sequence type; RT, PCR ribotype; SNP, single-nucleotide polymorphism; wgMLST, whole-genome MLST.Impact Statement

Clostridioides difficile is a major cause of healthcare-associated diarrhea and causes large infection outbreaks. Whole-genome sequencing is increasingly applied for genotyping C. difficile, with the objectives to monitor and curb the pathogen’s spread. We present a publicly accessible database for quality-controlled genome sequences from C. difficile that enables contextual interpretation of newly collected isolates by identifying related strains among published data. It also provides a nomenclature for genomic types to facilitate communication about transmission chains, epidemics, and phylogenetic lineages. Finally, we demonstrate that genome-based hierarchical clustering is largely compatible with previously used molecular typing techniques, thus enabling comparisons to earlier surveillance data.

Data Summary

All genome sequencing data were submitted to the European Nucleotide Archive ( under study numbers PRJEB33768, PRJEB33779 and PRJEB33780. The Clostridioides database within EnteroBase is publicly accessible at In addition, stand-alone versions of all EnteroBase tools are available at


The anaerobic gut bacterium Clostridioides difficile (formerly Clostridium difficile) [1] is the primary cause of antibiotic-associated diarrhea in Europe and North America [2]. Molecular genotyping of C. difficile isolates has demonstrated international dissemination of diverse strains through healthcare systems [3–5], the community [6] and livestock production facilities [7, 8]. Previously, genotyping was commonly performed by PCR ribotyping or DNA macrorestriction. More recent publications have documented that genome-wide single-nucleotide polymorphisms (SNPs) from whole-genome sequences provide improved discrimination, and such analyses have enabled dramatic progress in our understanding of the emergence and spread of epidemic strains [9–12] and the epidemiology of local transmission [13, 14]. Eyre and colleagues have argued that transmission of C. difficile isolates within a hospital environment can be recognized with high probability as chains of genomes, which differ by up to two SNPs whereas genomes, which differ by at least ten genomic SNPs represent unrelated bacteria [13, 15]. However, SNP analyses require sophisticated bioinformatic tools and are difficult to standardize [16, 17]. A convenient alternative to SNP-based genotyping is offered by the commercial software SeqSphere, which implements a core-genome multilocus sequence typing scheme (cgMLST) for the analysis of genomic diversity in 

C. difficile [18] and other organisms. Indeed, cgMLST [18] confirmed the prior conclusion from genomic SNP analyses [19] that a common clone of C. difficile had been isolated over two successive years at a hospital in China [18]. However, a recent quantitative comparison of the two methods showed that SeqSphere’s cgMLST achieved a low predictive value (41 %) for identifying isolate pairs that were closely related by the ≤2 SNPs’ criterion [20]. cgMLST of genomic sequences of a variety of bacterial pathogens can also be performed with EnteroBase (, which has been developed over the last few years with the goal of facilitating genomic analyses by microbiologists [21]. EnteroBase automatically retrieves Illumina short-read sequences from public short-read archives. It uses a consistent assembly pipeline to automatically assemble these short-reads into draft genomes consisting of multiple contigs, and presents the assembled genomes together with their metadata for public access [22]. It also performs the same procedures on sequencing data uploaded by its registered users. Assembled genomes that pass quality control are genotyped by MLST at the levels of seven-gene MLST, ribosomal MLST (rMLST), cgMLST and whole-genome MLST (wgMLST) [21, 22]. EnteroBase supports subsequent analyses based on either SNPs or cgMLST alleles using the GrapeTree or Dendrogram visualization tools [23]. EnteroBase also assigns these genotypes to populations by hierarchical clustering (HierCC), which supports the identification of close relatives at the global level [22]. Originally, EnteroBase was restricted to the bacterial genera Salmonella, Escherichia, Yersinia and Moraxella but since January 2018, EnteroBase has included a database for genomes and their metadata for the genus Clostridioides. In June 2020, EnteroBase contained 18 254 draft genomes of C. difficile plus one genome of C. mangenotii. These included over 900 unpublished draft genomes that were sequenced at the Leibniz Institute DSMZ, as well as 80 complete genome sequences based on Pacific Biosciences plus Illumina sequencing technologies. It also included 862 unpublished draft genomes that were sequenced at the Wellcome Sanger Institute.

Here we show that comparable levels of resolution and precision are attained by EnteroBase cgMLST as by SNP analyses. We also summarize the genomic diversity that accumulated during recurring infections within single patients as well as transmission chains within individual hospitals and between neighbouring hospitals in Germany, and show that it can be detected by HierCC. We also demonstrate that HierCC can be used to identify bacterial populations at various epidemiological levels ranging from recent transmission chains through to epidemic and endemic spread, and relate these HierCC clusters to genotypes that were identified by PCR ribotyping and k-mer-based diversity analysis. These observations indicate that cgMLST and HierCC within EnteroBase can provide a common language for communications and interactions by the global community who is combatting disease caused by C. difficile.Results

Implementation of MLST schemes in EnteroBase

cgMLST in EnteroBase consists of a defined subset of genes within a whole-genome MLST scheme that represents all single-copy orthologues within the pan-genome of a representative set of bacterial isolates. To this end, we assembled the draft genomes of 5232 isolates of C. difficile from public short-read archives, and assigned them to ribosomal sequence types (rSTs) according to rMLST, which indexes diversity at 53 loci encoding ribosomal protein subunits on the basis of existing exemplar alleles at PubMLST [24]. We then created a reference set of 442 genomes consisting of one genome of C. mangenotii [1], 18 complete genomes from GenBank, 81 closed genomes from our work and the draft genome with the smallest number of contigs from each of the 343 rSTs ( The Clostridioides pan-genome was calculated with PEPPA [25] and used to define a wgMLST scheme consisting of 13 763 genetic loci ( EnteroBase uses the wgMLST scheme to call loci and alleles from each assembly and extracts the allelic assignments for the subsets corresponding to cgMLST, rMLST and seven-gene MLST from those allelic calls [22]. The cgMLST subset consists of 2556 core genes, which were present in ≥98% of the reference set, intact in ≥94%, and were not excessively divergent (Fig. 1).Fig. 1.Criteria for inclusion in a cgMLST scheme of a subset of wgMLST genes based on their properties in a reference set of 442 genomes ( (a) Numbers of genes versus frequency (% presence) within the reference set. In total, 2634 genes satisfied the cut-off criterion of ≥98 % presence (dashed line). (b) Numbers of genes versus intact ORF (% intact ORF) within the 2634 genes from (a). Overall, 2560 genes satisfied the cut-off criterion of ≥94 % intact ORF (dashed line). (c) Frequency of allelic variants versus gene size among the 2560 genes from (b). The genetic diversity was calculated using the GaussianProcessRegressor function in the sklearn module in Python. This function calculates the Gaussian process regression of the frequency of genetic variants on gene sizes, using a linear combination of a radial basis function kernel (RBF) and a white kernel [57]. The shadowed region shows a single-tailed 99.9% confidence interval (≤3 sigma) of the prediction. Altogether, 2556 loci fell within this area and were retained for the cgMLST scheme, while four were excluded due to excessive numbers of alleles.Click to view

Comparison of cgMLST and SNPs for analyses of transmission chains

We compared the numbers of cgMLST allelic differences and the numbers of non-recombinant SNPs in isolates from multiple epidemiological chains. These included 176 isolates from four patients with recurring CDI (C. difficile infection), 63 isolates from four transmission chains in multiple hospitals [14, 19, 26], and a comprehensive sample of 1158 isolates collected over several years in four hospitals in Oxfordshire, UK [13]. A strong linear relationship (R2, 0.71–0.93) was found in all three analyses between the pairwise differences in cgMLST alleles and non-recombinant SNPs (Fig. S1, available in the online version of this article). The slope of the regression lines was close to 1.0, indicating a 1 : 1 increase in cgMLST allelic differences with numbers of SNPs. The same data were also investigated with cgMLST calculated with the commercial program SeqSphere [18], with similar correlation coefficients but a lower slope due to lesser discriminatory power of the SeqSphere cgMLST scheme (lower panels in Fig. S1).

Eyre et al. [13] concluded that direct transmission between two hospital patients can be detected because their bacterial genomes differ by two SNPs or less. Our analysis indicated that these transmission chains in the Oxfordshire dataset would also have been recognized by cgMLST in EnteroBase. Genomes that differed by two cgMLST alleles usually also differed by ≤2 SNPs according to a binary logistic regression model (probability=89%; 95% confidence interval, 88–89%) (Fig. 2). Of 3807 pairs of genomes with ≤2 allelic differences, 3474 also differed by ≤2 SNPs, yielding a positive predictive value of 91 % for identifying isolate pairs with ≤2 SNPs by EnteroBase cgMLST and a sensitivity of 62 % (≤2 cgMLST allelic differences were found in 3474 of 5707 pairs with ≤2 SNPs). The comparable values for SeqSphere were 78 % positive predictive value and 99% sensitivity.Fig. 2.Binary logistic regression model to determine the probability that two genomes are related at ≤2 SNPs, given a certain difference in their cgMLST allelic profiles, based on the Oxfordshire dataset [13]. The number of SNPs was encoded as a binary dependent variable (1 if ≤2 SNPs, 0 if otherwise) and the number of allelic differences was used as a predictor variable.Click to view

We also compared the genetic distances between 242 genomes from Oxfordshire, which had been isolated during the initial 6 months and 916 genomes from the actual testing period (April 2008 to March 2011) [13]. Overall, 35% (318/916) of the latter genomes matched at least one genome collected earlier by two or less EnteroBase cgMLST alleles and 34% (316/916) matched an earlier genome by ≤2 SNPs. The two sets of genomes were 89% concordant. Thus, cgMLST is equivalent to SNP analysis for detecting inter-patient transmission chains.

Hierarchical clustering for tracing local and regional spread

SNP analyses are computer intensive, and are only feasible with limited numbers of genomes [27]. cgMLST-based relationships can be analysed for up to 100 000 genomes with GrapeTree, but analyses involving more than 10 000 genomes remain computer intensive [23]. EnteroBase implements single-linkage hierarchical clustering (HierCC V1) of cgMLST data in pairwise comparisons at multiple levels of relationship after excluding missing data [22]. These are designated as HC0 for hierarchical clusters of indistinguishable core-genome sequence types (cgSTs), HC2 for clusters with pairwise distances of up to two cgMLST alleles, etc. EnteroBase presents cluster assignments for C. difficile at the levels of HC0, HC2, HC5, HC10, HC20, HC50, HC100, HC150, HC200, HC500, HC950, HC200 and HC2500. Here we address the nature of the genetic relationships that are associated with these multiple levels of HierCC among 13 515 publicly available C. difficile genomes, and examine which levels of pairwise allelic distances correspond to epidemic outbreaks and to endemic populations.

In our analyses of 176 C. difficile isolates from four patients with two recurrent episodes of CDI, multiple genomes were assigned to patient-specific HC2 clusters, some of which were isolated from the initial episode as well as the recurrence 80–153 days later (Fig. 3, patients D, F and G; 4 to 36 isolates had been collected per episode; Table S1). For these patients, relapsing disease likely reflected continued colonization after initially successful therapy. However, some isolates from patient F differed by 12–21 cgMLST alleles from the bulk population (Fig. 3), which indicates that the patient was co-infected simultaneously with multiple related strains. In patient E, the two genomes from the two CDI episodes differed by >2000 allelic differences (Fig. 3), which indicates that the second incident of CDI represented an independent infection with an unrelated strain. Hence, discrimination between relapse and reinfection based on cgMLST appears to be straightforward except that two episodes of CDI might arise by reinfection with identical strains from an environment that is heavily contaminated with C. difficile spores [28]. We note that the time intervals (16–22 weeks) investigated here exceeded the currently recommended threshold of 8 weeks for surveillance-based detection of CDI relapses [29, 30] but still yielded almost identical strains in three of four patients.Fig. 3.Minimum-spanning trees indicating the population structure of C. difficile in four patients with recurrent CDI episodes. Red, first episode; blue, second episode.Click to view

Our examinations of multiple local outbreaks have revealed individual, outbreak-specific HC2 clusters. However, it is also conceivable that multiple HC2 clusters might be isolated from a single epidemiological outbreak due to the accumulation of genetic diversity over time. Alternatively, multiple HC2 clusters within a single outbreak may represent the absence of crucial links due to incomplete sampling. Incomplete sampling of outbreaks is not unlikely because asymptomatic patients are only rarely examined for colonization with C. difficile [31–33] even though they may constitute an important reservoir for transmission. Indeed, some of the outbreaks investigated here did consist of more than one HC2 cluster (Fig. 4). For example, nine isolates from a recently reported ribotype 018 (RT018) outbreak in Germany [26] encompassed four related HC2 clusters, and outbreaks with RT027 and RT106 in a hospital in Spain [14] were each affiliated with two or three HC2 clusters (Fig. 4).Fig. 4.Neighbour-joining trees based on cgMLST showing the phylogenetic relationships among C. difficile isolates from previously published CDI outbreaks as indicated [14, 19, 26]. Nodes are coloured by HC2. CC, cgST complex, i.e. related at level HC150; RT, PCR ribotype. The scale, indicating one allelic difference, applies to all trees.Click to view

We identified 23 HC2 clusters encompassing 133 genome sequences in a dataset of 309 C. difficile genome sequences collected from CDI patients in six neighbouring hospitals in Germany. These HC2 clusters were associated with individual hospitals (Χ2P=8.6×10−5; Shannon entropy, P=4.2×10−5) and even with single wards in these hospitals (Χ2P=0.01; Shannon entropy, P=6.2×10−3). We investigated whether these HC2 clusters reflected the local spread of C. difficile within institutions by retrospective analyses of patient location data. Sixty-six patients (50 %) were found to have had ward contacts with another patient with the same HC2 cluster (median time interval between ward occupancy: 63 days; range, 0 to 521). These results are consistent with the direct transmission on wards of C. difficile isolates of the same HC2 cluster (Fig. 5). For patients such as P1 and P2 where the shared ward contacts were separated in time (Fig. 5), transmission may have occurred indirectly through asymptomatically colonized patients or from a common reservoir, such as environmental spore contamination [14, 31, 32]. We also detected 15 HC2 clusters that included isolates from two or more hospitals in the region. Subsequent analyses of patient location data confirmed that some of these HC2 clusters were associated with patient transferrals between the hospitals (Fig. 5). Hence, hierarchical clustering of C. difficile genome sequences in conjunction with retrospective analysis of patient movements revealed multiple likely nosocomial transmission events, none of which had been detected previously by routine surveillance.Fig. 5. Timelines of two transmission chains discovered retrospectively through inspection of files from CDI patients with closely related C. difficile isolates (HC2). Colours indicate hospital wards, ‘X’ indicates a diagnosis of CDI, and arrows indicate presumed transmission pathways. Minimum-spanning trees indicating genomic distances among C. difficile isolates are shown on the right. Upper panel: patient P1 was diagnosed with CDI in hospital H2 and transferred to hospital H3 15 days later. Another five and 6 days later, respectively, patients P2 in hospital H2 and P3 in hospital H3 got diagnosed with CDI with closely related strains. Both these patients were on the same wards as the initial patient, who probably had been the source for the pathogen. Since there was no temporal overlap between patient P2 and the other patients in hospital H2, the transmission may have occurred indirectly, possibly through environmental contamination. Lower panel: another putative transmission chain involved three patients that had shared time in hospital H2. Patients P4 and P5 got diagnosed with CDI on the same day after they had shared 7 days in this hospital, albeit on different medical wards. The third patient developed CDI with the same C. difficile cgST 4 days after being transferred to another hospital (h5), but had previously stayed at hospital H2 during the time when CDI got diagnosed in the first two patients. Since the three patients stayed on different wards in hospital H2, transmission presumably occurred indirectly.Click to view

Hierarchical clustering for identification of epidemic strains and endemic populations

The international epidemic spread of C. difficile over up to 25 years has been inferred previously on the basis of molecular epidemiology with lower resolution techniques [34]. For multiple representatives of those epidemic strains in EnteroBase, the majority of these epidemic groups corresponded to HC10 clusters, including epidemic RT017 [11] (HC10_17), the two fluoroquinolone-resistant lineages of RT027 [9] (HC10_4, HC10_9), or livestock-associated RT078/126 [35] (HC10_1) (Fig. 6).Fig. 6.Phylogenetic structure of three international C. difficile epidemics, each of which has spread for about 25 years [9, 11]. Within each epidemic, the majority of isolates are related at level HC10, as indicated by the colours. CC, cgST complex, i.e. related at level HC150; RT, PCR ribotype.Click to view

Endemic populations have also been described by ribotyping and phylogenetic analyses, some of which have acted as sources for the emergence of epidemic strains [2, 9]. Many endemic populations seem to be represented by HC150 clusters. Clustering at HC150 was well supported statistically (Fig. S2), and the frequency distribution of pairwise genomic distances indicated that multiple database entries clustered at <150 cgMLST allelic differences (Fig. S3). HC150 clusters also correlated well with k-mer-based classification [36]. When applied to the dataset of 309 C. difficile genomes from six hospitals in Germany, the two methods implemented in EnteroBase and PopPUNK found 51 and 48 clusters, respectively, the majority of which coincided (adjusted Rand coefficient, 0.97).

A cgMLST-based phylogenetic tree of 13515 C. difficile genomes showed 201 well-separated HC150 clusters, each encompassing a set of related isolates, plus 209 singletons (Fig. 7). Because these HC150 clusters are based on cgMLST genetic distances, we refer to them as ‘cgST complexes’, abbreviated as CCs. Genomes from each of the major CCs have been collected over many years in multiple countries, indicating their long-term persistence over wide geographic ranges (Table 1).Fig. 7.Rapid-neighbour-joining phylogenetic tree based on cgMLST variation from 13 515 C. difficile genomes. Colours and numerals indicate CCs (HC150 clusters) with ≥10 entries, and information on predominant PCR ribotypes is provided in brackets.Click to view

Table 1.

Characteristics of cgST complexes (CC) with ≥100 entriesToggle display:Table 1.  Open Table 1. fullscreen 

CC (HC150)PCR RibotypeNumber of entriesSampling yearsNumber of countries% isolates in HC2>21% isolates from animal hosts
1078, 126, 06612221994–2018266117
6020, 4047681995–201714431
22106, 5005311997–20177593
71014, 0203152004–201716401
178018, 3562432006–20177520
141001, 0261072007–2016270
49011, 056, 4461032001–20175350
1isolates in HC2 clusters with >2 entries.

We compared HC150 clustering with PCR ribotyping for 2263 genomes spanning 84 PCR ribotypes for which PCR ribotyping data were available in EnteroBase. These included 905 genomes, which we ribotyped (Table S2), as well as several hundred other genomes for which ribotype information was manually retrieved from published data. The correlation between HC150 clustering and ribotyping was high (adjusted Rand coefficient, 0.92; 95% confidence interval, 0.90–0.93). However, our analysis also revealed that PCR ribotypes did not always correspond to phylogenetically coherent groupings. PCR ribotypes 002, 015 and 018 were each distributed across multiple phylogenetic branches (Fig. 8). Furthermore, some genomes with indistinguishable cgMLST alleles were assigned to multiple ribotypes, including RT001/RT241, RT106/RT500 and RT126/RT078 (Fig. 8Table 1). In these cases, both ribotypes occurred in several, closely related clades (Fig. 8), indicating that similar ribotype banding patterns had evolved multiple times. In contrast, HC150 clusters corresponded to clear-cut phylogenetic groupings within a phylogenetic tree of core genes (Fig. 8b).Fig. 8.Rapid-neighbour-joining phylogenetic tree based on cgMLST variation from 2263 C. difficile genomes, for which PCR ribotyping information is available. Upper panel: nodes are coloured by PCR ribotype as indicated. Lower panel: nodes are coloured by CC (HC150 clusters).Click to view

Higher population levels

HierCC can also identify clusters at still higher taxonomic levels, up to the levels of species and sub-species [22]. In C. difficile, HC950 clusters seem to correspond to deep evolutionary branches (Fig. S4) and HC2000 clusters were congruent with the major clades reported previously [37], except that cluster HC2000_2 encompassed clade 1 plus clade 2 (Fig. S5). Finally, HC2500 may correspond to the subspecies level, because it distinguished between C. difficile and distantly related ‘cryptic clades’ (Fig. S6).Discussion

Infectious disease epidemiologists frequently seek to know if new isolates of bacterial pathogens are closely related to others from the different geographical origin, i.e. if they are part of a widespread outbreak. Unlike a previous cgMLST implementation [18], EnteroBase supports this goal by taking full advantage of rapidly growing, public repositories of short-read genome sequences [22]. In contrast to short-read archives, however, where stored sequence data are not readily interpretable without specialized bioinformatic tools [38], EnteroBase enables contextual interpretation of a growing collection (18 254 entries as of June 2020) of assembled, quality-controlled C. difficile genome sequences and their associated metadata. At least the collection date (year), the geographic origin (country), and the source (host species) are available for the majority of database entries. Importantly, phylogenetic trees based on cgMLST allelic profiles from many thousand bacterial genomes can be reconstructed within a few minutes, whereas such calculations are currently prohibitively slow based on SNP alignments [22]. Genome-sequencing reads from newly sampled C. difficile isolates can be uploaded to EnteroBase and compared to all publicly available genome data within hours, without requiring any command-line skills.

We demonstrate that the application of cgMLST to investigations of local C. difficile epidemiology yields results that are quantitatively equivalent to those from SNP analyses. This is a major advance because SNP analyses require specific bioinformatic skills and infrastructure, are time-consuming and not easily standardized [16]. A web platform for centralized, automated SNP analyses on bacterial genomes is limited to food pathogens currently and does not offer any analyses on C. difficile genomes [39]. Even though a cgMLST scheme for C. difficile had been published recently [18], its ability to identify closely related isolates and the inferred genomic distances was shown to be inferior to SNP analyses due to an excess of errors introduced by the de novo assembly of sequencing reads and a lack of per-base quality control [20]. In EnteroBase, cgMLST is also based on de novo assembly, but EnteroBase uses Pilon [40] to polish the assembled scaffolds and evaluate the reliability of consensus bases of the scaffolds, thereby achieving comparable accuracy to mapping-based SNP analyses. When applied to a large dataset of C. difficile genomes from hospital patients in the Oxfordshire region (UK), cgMLST and SNP analysis were largely consistent (89% match) at discriminating between isolates that were sufficiently closely related to have arisen during transmissions chains from others that were epidemiologically unrelated.

After assembly, draft genomes contain missing data and many cgSTs have unique cgST numbers but are identical to other cgSTs, except for missing data. Hence, individual cgST numbers are only rarely informative. However, indistinguishable cgSTs are clustered in common HierCC HC0 clusters, which ignore missing data. In June 2020, the Clostridioides database contained >12 000 HC0 clusters, indicating that the majority of genomes was unique. Similarly, EnteroBase provides cluster designations at multiple levels of HierCC, enabling rapid identification of all cgSTs that are related at multiple levels of genetic distance. The data presented here shows that HierCC designations can facilitate communications between researchers, clinicians and public-health officials about transmission chains, epidemic outbreaks, endemic populations and higher phylogenetic lineages up to the level of subspecies.

EnteroBase cgMLST identified numerous HC2 clusters of strains in C. difficile isolates that seem to have arisen during transmission chains in six neighboring hospitals in Germany. These assignments were in part consistent with retrospective investigation of patient location data, although none of the nosocomial outbreaks (defined by German law as two or more infections with likely epidemiological connections []) had been detected previously by standard epidemiological surveillance by skilled clinical microbiologists. Recent publications propose that prospective genome sequencing of nosocomial pathogens should be applied routinely at the hospital level to guide epidemiological surveillance [41]. Our data indicates that the combination of genome sequencing with cgMLST and HierCC may identify nosocomial transmission routes of C. difficile more effectively than presently common practice, and hence could help to reduce pathogen spread and the burden of disease. Reliable identification of transmission chains requires interpretation of pathogen genome sequence data in its epidemiological context, however [42].

HierCC will also enable comparisons to previously published data because we have provided a correspondence table between HC150 clusters and PCR ribotypes (Table 1). Rarefaction analysis indicated that the currently available genome sequences represent about two-thirds of extant HC150 (CC) diversity, which extrapolated to about 600 CCs (Fig. S7). At least some of this enormous diversity may be due to the occupation of multiple, distinct ecological niches, as exemplified by differential propensities for colonizing non-human host species (Table 1) [43, 44]. Individual CCs may also differ in their aptitudes for epidemic spread, as indicated by drastically different proportions of genomes assigned to HC2 chains: only 7% of CC141 were assigned to HC2 clusters versus 35% of CC34 and 77% of CC4 (Table 1). A full understanding of the population structure of C. difficile and its relationship to epidemiological patterns will require additional study because many of the clusters described here have not yet been studied or described. However, this task can be addressed by the global community due to the free public access to such an unprecedented amount of genomic data from this important pathogen.Methods


In total, 309 C. difficile isolates were collected at a diagnostic laboratory providing clinical microbiology services to several hospitals in central Germany. To assemble a representative sample, we included the first 20 isolates from each of six hospitals from each of three consecutive calendar years (Table S2). For the investigation of recurrent CDI, a set of 176 C. difficile isolates were collected in a diagnostic laboratory in Saarland, Germany. Here, primary stool culture agar plates were stored at 4 °C for 5 months to eventually enable the analysis of multiple plates representing episodes of recurrent C. difficile infection from individual patients, who had developed the recurrent disease by then and could be chosen with hindsight. It was attempted to pick and cultivate as many bacterial colonies from each selected plate as possible, resulting in 6 to 36 isolates per CDI episode (Table S1). In addition, we sequenced the genomes from 383 isolates that had been characterized by PCR ribotyping previously, including 184 isolates sampled from piglets [8], 71 isolates from various hospitals in Germany [3], and 108 isolates from stool samples collected from nursing home residents (unpublished; Table S2).

PCR ribotyping

PCR ribotyping was performed as described previously [45], applying an ABI Prism 3100 apparatus for capillary electrophoresis and comparing banding patterns to the Webribo database ( sequencing

For Illumina sequencing, genomic DNA was extracted from bacterial isolates by using the DNeasy Blood and Tissue kit (Qiagen), and libraries were prepared as described previously [46] and sequenced on an Illumina NextSeq 500 machine using a Mid-Output kit (Illumina) with 300 cycles. For generating complete genome sequences, we applied SMRT long-read sequencing on an RSII instrument (Pacific Biosciences) in combination with Illumina sequencing as reported previously [46]. All genome sequencing data were submitted to the European Nucleotide Archive ( under study numbers PRJEB33768, PRJEB33779 and PRJEB33780

.SNP detection and phylogenetic analysis

Sequencing reads were mapped to the reference genome sequence from C. difficile strain R20291 (sequence accession number FN545816) by using BWA-MEM and sequence variation was detected by applying VarScan2 as reported previously [46]. Sequence variation likely generated by recombination was detected through analysis with ClonalFrameML [47] and removed prior to determination of pairwise sequence distances [15] and to construction of maximum-likelihood phylogenetic trees with RAxML (version 8.2.9) [48].Genome assembly, quality control and wgMLST allele calling

Genomic data was processed by automated pipelines within EnteroBase, which were described in detail previously [22]. Briefly, Illumina sequencing reads were assembled by using Spades v3.10 [49] and assemblies were improved by applying Pilon [40]. To pass quality control, assemblies were required to comply with the following thresholds: total length, 3.6 to 4.8 Mbp; N50, ≥20 000; the number of contigs, ≤600; number of unresolved nucleotides, ≤3%; the proportion of Clostridioides sequences, >65 % (as determined by Kraken with MiniKraken database [50]). Assemblies were aligned to exemplar alleles by using blastn [51] and the usearch module UblastP [52], and allele numbers, STs, and HC numbers assigned by using the EnteroBase module MLSType [22]. All EnteroBase tools are available at

To determine the probability that two genomes are related at ≤2 SNPs, given a certain difference in their cgMLST allelic profiles, we inferred a logistic regression model using R ([53], pp. 593–609). Genomic relatedness was encoded as a binary response variable (1 if ≤2 SNPs, 0 if otherwise) and the number of core-genome allelic differences was used as a predictor variable. We applied this model to a dataset of 1158 genome sequences from a previous study, representing almost all symptomatic CDI patients in Oxfordshire, UK, from 2007 through 2011 [13]. While that original study had encompassed a slightly larger number of sequences, we restricted our analysis to the data (95 %) that had passed quality control as implemented in EnteroBase [21]. We used the SNP data from Eyre’s report [13].

The hierarchical single-linkage clustering of cgMLST sequence types was carried out as described [22] for all levels of allelic distances between 0 and 2556. We searched for stable levels of differentiation by HierCC according to the Silhouette index [54], a measure of uniformity of the divergence within clusters. The Silhouette index was calculated based on d^’, a normalized genetic distance between pairs of STs, which was calculated from their allelic distance d as follows: d^’=1-(1-d)^(1/l), where l is the average length (937 bp) of the genes in the cgMLST scheme.

We further evaluated the ‘stability’ of hierarchical clustering using two other criteria. The Shannon index is a measure of diversity in a given population. The Shannon index drops from nearly 1 in HC0, because most cgSTs are assigned to a unique HC0 cluster, to 0 in HC2500, which assigns all sequence types to one cluster. The gradient of the Shannon index between the two extremes reflects the frequencies of coalescence of multiple clusters at a lower HC level. Thus, the plateaus in the curve correspond to stable hierarchical levels, where the Shannon index does not change dramatically with HC level. We also evaluated the stability of hierarchical clustering by pairwise comparison of the results from different levels based on the normalized mutual information score [55] (Fig. S3).

For clustering C. difficile diversity with PopPUNK [36], we used a sketch size of 105 and a K value (maximum number of mixture components) of 15. Of note, the resulting number of clusters for the tested dataset was identical for all K between 15 and 30.

To estimate concordance between cgMLST-based hierarchical clustering and PCR ribotyping or PopPUNK clustering, respectively, we calculated the adjusted Rand coefficient [56] by using the online tool available at To test statistical associations of HC2 clusters with specific hospitals and hospital wards, respectively, we compared Χ2 values and normalized Shannon entropy values (R package ‘entropy’ v.1.2.1) from contingency tables containing real isolate distributions (Table S3) and randomly permuted distributions (n=1000), by using the non-parametric, two-sided Mann–Whitney U test (R package ‘stats’ v.3.5.0).

This work was partially funded by the German Center for Infection Research (DZIF), by the Federal State of Lower Saxony (Niedersächsisches Vorab VWZN2889/3215/3266), by the EU Horizon 2020 programme (grant agreement number 643476), the Wellcome Trust (098051), and the UK Medical Research Council (PF451). EnteroBase development was funded by the BBSRC (BB/L020319/1) and the Wellcome Trust (202792/Z/16/Z), and the salary of Z.Z. was also provided by The Wellcome Trust. The funders had no role in the study design, preparation of the article, or decision to publish.


We thank Vera Junker, Simone Severitt, Nicole Heyer and Carola Berg for excellent technical assistance, Johannes Sikorski for help with R, and David Eyre for supplying SNP data from his 2013 paper in tabular format.Author contributions

M.A. and U.N. designed the study. M.F., Z.Z., M.S., J.P.M., M.G., T.R., B.B., C.S., J.O., M.B., A.I., L.v.M., F.K., S.G.F., O.Z., U.G., M.A., and U.N. analyzed the data. L.v.M., C.S., O.Z., U.G., R.C., R.d.C., N.K., T.D.L., T.A.K. and S.N. acquired bacterial isolates and sequence data. M.F., Z.Z., M.A., and U.N. wrote the manuscript and all authors reviewed and edited the manuscript and approved the final version.

to review the article in its entirety please click on the following link to be redirected. Thank you.

Monday, April 27th – 6:00 p.m. EST Leading Gastroenterologist’s Caterina Oneto, MD & Paul Feuerstadt, MD Host C. diff. Global TeleSupport Network

MONDAY,  April 27th   –  6:00 p.m. EST
Hosts and Co-Directors

Doctors Caterina Oneto, MD &
Paul Feuerstadt, MD


Topic:  Doctors Oneto and Feuerstadt will discuss C. difficile Infections; The What, Where and How.  There will be opportunities to ask a  brief question to the physicians.  We appreciate Dr.’s Oneto and Dr. Feuerstadt for donating their time to discuss C. difficile Infections and to provide information regarding prevention, treatments available, and environmental safety products available.   Join Dr. Oneto and Dr. Feuerstadt’s session hosted on the fourth Monday of each month.
Via: Teleconference Call:  1 – 646 -927 – 0297   Conference ID:  123560#
3:00 p.m. PT     4:00 p.m. MT     5:00 p.m. CT    6:00 p.m ET

NOTE:  The Physicians will not prescribe, diagnose, or provide medical assessment answers to any individuals participating in their support session.  Please contact the Physician providing care for a C. diff. Infection or other diagnoses that are being treated.    Thank you.



Support and information sessions are for everyone especially for —

  • Families.
  • Clinicians,
  • C. diff. survivors continuing their recovery from a prolonged illness.
  • Patients working their way through any long-term wellness draining diagnosis.

All Sessions are FREE and accessible from the USA and 57 countries  *

Support is available to anyone seeking additional information with the desire to speak with others that understand the journey.

  • PLEASE NOTE *  If you, or anyone you know, are experiencing mental or physical symptoms causing pain, fever, discomfort, C. difficile symptoms or changes in a diagnosed infection, or a change in emotional behavior or having suicidal thoughts, DO NOT wait for a scheduled support session.  Contact a physician or seek medical attention at a local clinic or hospital immediately. Thank you.

The C. diff. Global TeleSupport Network program is the first-ever FREE GLOBAL patient and family educational support program developed by a U.S. non-profit 501(c)(3) — The C Diff Foundation is dedicated to educating and advocating for C. difficile infection prevention, treatments, clinical trials, support, and environmental safety worldwide.

CDC Studies Show Decline in C. difficile and Multidrug-Resistant Bacteria In USA Hospitals

Published April 2, 2020

Declines in C diff

2011 – 2017

The decline in C difficile infections may be another sign of improved infection prevention and antibiotic stewardship in US hospitals

C difficile, a bacterium that causes severe diarrhea, is the primary cause of hospital-associated diarrhea and is linked primarily to broad-spectrum antibiotic use, which can disrupt the balance of bacteria in the gut. Reduction of C difficile prevalence has been among the goals of efforts to improve infection prevention and antibiotic use in US hospitals over the past decade.

To assess progress in reducing C difficile infections, CDC researchers used data from the Emerging Infections Program (EIP), which conducts C difficile surveillance in 35 counties in 10 states.

As with the other study, they classified infections as either healthcare-associated or community-associated. Although primarily considered an infection that affects hospital patients, C difficile infections in people with no recent hospital or nursing home stays have been on the rise.

The researchers also adjusted their findings to account for increased use of nucleic acid amplification testing (NAAT) over the study period. NAAT is more sensitive than other types of
C difficile testing but cannot distinguish between colonization and infection, which has raised concerns about overdiagnosis.

The percentage of cases diagnosed using NAAT at the EIP hospitals increased from 55% in 2011 to 83% in 2017.

The initial estimate showed a small decline in the total national burden of C difficile infection—from 476,000 cases (154.9 cases per 100,000 population) in 2011

to 462,100 cases (143.6 cases per 100,000 population) in 2017.

But after adjusting NAAT use to the 2011 rate of 55%, total
C.  difficile
infections fell by 24% from 2011 through 2017, driven by a 36% decrease in healthcare-associated infections.

Total hospitalizations for C difficile infection fell by 24%.

The adjusted estimate for community-associated C difficile infections—which accounted for 50% of all infections in 2017—saw no change.

The authors of the study say the reductions in healthcare-associated C difficile could be linked to better adherence to recommended infection-prevention practices, as well as to reduced use of fluoroquinolone antibiotics in hospitals.


In the midst of the COVID-19 pandemic, new data published today in the New England Journal of Medicine (NEJM) provides a glimmer of good news on the infectious disease front.

A study conducted by researchers from the Centers for Disease Control and Prevention (CDC) found that the incidence of infections caused by four multidrug-resistant (MDR) organisms (MDROs) decreased in US hospitals from 2012 through 2017, with the declines ranging from 20% to 39%. While the burden of MDR infections in US hospitals remains substantial, and more work is need to sustain the progress that’s been made, the authors of the study say the findings, which formed the basis for the CDC’s 2019 report on antibiotic resistance, are encouraging.

“For some resistant pathogens, encouraging reductions have been observed in recent years, suggesting that current prevention efforts, particularly infection control interventions focused on healthcare settings, are yielding important benefits,” lead author John Jernigan, MD, of the CDC’s Division of Healthcare Quality Promotion, told CIDRAP News.

In another study today in NEJM, a different team of CDC researchers reported that the national burden of Clostridioides difficile infection and associated hospitalization decreased by nearly a quarter from 2011 through 2017, largely owing to a decline in healthcare-associated C difficile infections.

Declines in 4 MDR pathogens

For the study on MDR infections, Jernigan and his colleagues used electronic health record data from 890 US short-term acute care hospitals to generate a national case count and examine temporal trends for infections caused by the primary MDR pathogens associated with healthcare: methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter species, MDR Pseudomonas aeruginosa, and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.

In 2017, these pathogens, which are considered urgent or serious threats by the CDC because they can cause severe, hard-to-treat invasive infections and spread easily in healthcare settings, caused an estimated 622,390 infections among hospitalized patients. Of these cases, 83% (517,818) were community-onset (either obtained in the community or within the first 3 days of hospitalization) and 17% (104,572) were hospital-onset.

From 2012 through 2017, the researchers found that the incidence decreased for infections caused by MRSA (from 114.18 to 93.68 cases per 10,000 hospitalizations), VRE (24.15 to 15.76 cases per 10,000 hospitalizations), carbapenem-resistant Acinetobacter species (3.33 to 2.47 cases per 10,000 hospitalizations), and MDR P aeruginosa (13.10 to 9.43 cases per 10,000 hospitalizations). There was no significant change on the incidence of CRE infections (3.36 to 3.79 cases per 10,000 hospitalizations).

Although the study did not determines the reasons for these declines, Jernigan says it’s likely that improved infection prevention and control efforts in hospitals have contributed to reducing the spread of these pathogens, particularly MRSA and VRE, which tend to be prevalent in patients who’ve had a lot of healthcare exposure. The incidence of hospital-onset MRSA and VRE declined nearly twice as fast as in community-onset cases.

“During the past decade, healthcare decision makers have placed increased emphasis on infection control in healthcare, including efforts to improve implementation of strategies for preventing device- and procedure-related infections and general infection control measures such as hand hygiene,” he said. “In addition, there has been widespread implementation of MDRO-specific measures designed to prevent healthcare transmission of the pathogens we studied, and many healthcare systems have increased emphasis on antimicrobial stewardship as well.”

Neil Clancy, MD, an associate professor of medicine and infectious disease specialist at the University of Pittsburgh who was not involved in the study, says the data are a welcome bright spot as the nation grapples with the COVID-19 pandemic.

“Taken together, these data suggest that national efforts over the past decade in antimicrobial stewardship and infection prevention, many led by CDC, are making a positive impact on AMR [antimicrobial resistance] in this country,” Clancy said. He’s particularly encouraged by the declines in two of the most worrisome MDR gram-negative (GN) pathogens—carbapenem-resistant Acinetobacter and MDR Pseudomonas.

“Although infections by these pathogens are less common than those caused by MRSA, there are fewer antibiotics active against MDR-GNs,” he said. “Moreover, these bacteria are often acquired by very sick patients in the hospital, so their impact on death and poor outcomes in general is high.”

Notes of caution

But there’s some bad new with the good news. The study also found a 53% rise in incidence of infections caused by ESBL-producing Enterobacteriaceae, largely driven by an increase in community-onset infections. The authors hypothesize that this increase could be linked to Escherichia coli sequence type (ST)131—an epidemic MDR E coli strain that has become a primary cause of antibiotic-resistant infections worldwide and is the most common cause of urinary tract infections.

“More widespread emergence of ESBL bacteria, particularly among otherwise healthy people who are not in the hospital or nursing homes, but rather living in the community, is a potential public health nightmare,” said Clancy, noting that infections caused by ESBL bacteria are also problematic because there are currently no active oral antibiotics for treating them.

Clancy also pointed out that, with 83% of the MDR infections found to be originating in the community, it’s not only the sick people in hospitals who need to worry about those infections.

“The study serves as a reminder that antimicrobial resistance, over the long-term, is as big a public health threat as emerging viral pandemics,” he said.

In an editorial that accompanies the study, infectious disease experts from the University of Washington and the University of California, San Diego, say the results of the study suggest that when it comes to antibiotic resistance, the glass is half full. While the observed reductions indicate that progress is being made, the rise in community-onset MDR infections, and the dwindling pipeline of new antibiotics, underscore the challenges that remain and the need for innovative approaches.

“We cannot afford to be complacent about recent progress in the health care setting, because resistant pathogens are still too common in most institutions, and favorable trends can be readily reversed,” they write. “Moreover, the continued presence of MDR organisms and the rapid emergence of antimicrobial resistance to recently introduced agents mean that new strategies for the treatment of infections by MDR organisms must continue to be a high priority.”

Jernigan agrees.

“Innovative interventions and strategies, tailored for the spectrum of healthcare and community settings, will be needed to sustain progress in combating antibiotic resistance,” he said.



Study Shows Older Adults Diagnosed With Cancer Have a Higher Risk Of Acquiring a C. diff. Infection

Older adults with cancer have a higher risk of developing Clostridioides difficile infection (CDI) than those without a cancer diagnosis, according to a new study.

The risk is particularly high for those with hematologic malignancies and those with recently diagnosed solid tumors

and distant metastasis (Emerg Infect Dis 2019;25[9]:1683-1689).

“CDI is the leading cause of healthcare-associated infection,” said Mini Kamboj, MD, the chief medical epidemiologist of infection control at Memorial Sloan Kettering Cancer Center in New York City. “Older adults over the age of 65 are at a higher risk for developing CDI and related complications. Our study demonstrates that this risk in advanced age is further amplified by a cancer diagnosis.”

Dr. Kamboj and her colleagues conducted a retrospective cohort study using population-based Surveillance, Epidemiology, and End Results/Medicare–linked data to assess CDI occurrence during 2011. Medicare beneficiaries with and without cancer were included. For those with cancer, patients with solid (breast, colon, lung, prostate, and head and neck) and hematologic (lymphoma, myeloma, and leukemia) tumors diagnosed from 2006 to 2010 were included. All included participants were at least 66 years of age at the time of diagnosis. They also included patients at least 66 years of age at the start of 2011 with no history of cancer.

Of the 93,566 beneficiaries in the study, 2.6% were diagnosed with CDI during the study period. Of these, 2.8% of the patients with cancer had CDI, compared with 2.4% of the noncancer patients. The incidence of CDI also increased with age: from 1.9% among patients 66 to 69 years of age to 2.9% among patients at least 85 years of age.

To read the article in its entirety please click on the following link: